SCHEDULE 13G/A: Vivo Opportunity Fund Discloses 9.7% Stake in Soleno Therapeutics
Beneficial Ownership Disclosure
Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have filed an amended Schedule 13G disclosing a 9.7% beneficial ownership stake in Soleno Therapeutics, Inc.
Summary
- Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC reported beneficial ownership of 4,458,294 shares of Soleno Therapeutics, Inc. Common Stock.
- This ownership represents 9.7% of the Issuer's outstanding Common Stock.
- The percentage of class was calculated based on 45,857,291 shares of Common Stock outstanding as of February 26, 2025, as reported in Soleno Therapeutics' Quarterly Report on Form 10-Q filed on February 28, 2025.
- The event requiring this filing occurred on March 31, 2025.
- The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of Soleno Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It merely reports a significant stake held by an institutional investor.
Positives
- A significant institutional investor, Vivo Opportunity Fund Holdings, L.P., holds a substantial 9.7% stake in Soleno Therapeutics, Inc., which can be interpreted as a vote of confidence in the company's prospects.
Future Outlook
NA
Industry Context
This filing indicates continued investment by a specialized fund in the biotechnology sector, where strategic stakes by institutional investors can signal confidence in a company's pipeline or market position. Soleno Therapeutics operates within this sector, focusing on therapeutic developments.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date as of which 45,857,291 shares of Common Stock were outstanding, used for percentage calculation. |
| 02/28/2025 | Date Soleno Therapeutics' Quarterly Report on Form 10-Q was filed with the SEC, reporting the outstanding shares. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
Keywords
Soleno Therapeutics, Vivo Opportunity Fund, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.